UnitedHealth Group (UNH) is the largest U.S. health insurer and the parent of Optum, its care-delivery, pharmacy-benefit and health-analytics arm, insuring tens of millions of Americans through UnitedHealthcare. In Wednesday's session the stock traded at $359.29, a decline of $30.39, or 7.80%, against Tuesday's close of $389.68 — a confirmed move to the downside that extends a two-day rout of roughly 13%. The immediate cause is regulatory: a newly proposed federal framework that would sharpen Medicare Advantage payment audits and reach back nearly a decade into previously booked revenue, compounded by political pressure on the company's size and structure.
The core problem is arithmetic. The CRUSH proposed rule, released Monday, would codify risk-adjustment data validation audits without a fee-for-service adjuster and allow sampled coding errors to be extrapolated across an entire contract, beginning with payment year 2018. CMS estimates the approach could recover about $9 billion per payment year across the industry, part of nearly $90 billion in projected federal savings through 2036.
No insurer is more exposed. Medicare Advantage accounts for roughly 44% of UnitedHealth's revenue, and the company is the program's dominant participant. Management has not quantified or reserved against its potential liability, which leaves analysts modeling against an unknown bill that would be paid out of an operating margin already compressed to about 4.8%. Wednesday's selling reflects investors moving from "how large is the penalty" to "the penalty is large enough to reset the earnings base." Public comment on the rule runs through Jan. 19, 2027, so the final shape remains fluid.
A second, less quantifiable overhang is political. Renewed calls from Senator Elizabeth Warren to break up large vertically integrated health conglomerates — explicitly naming UnitedHealth alongside CVS Health (CVS) and Cigna — reintroduced structural risk that investors had largely discounted during the stock's 2026 rebound. Proposals of this kind rarely become law quickly, but they widen the risk premium attached to a company that owns an insurer, a pharmacy-benefit manager and a provider network.
Sentiment was not helped by a report that UnitedHealth is selling a stake in portions of its Optum Health Florida operations to private equity firm TPG. Divestitures can be read as disciplined portfolio pruning, but in the current climate the market interpreted the transaction as evidence of margin pressure in a segment that swung to an operating loss amid rising medical costs.
The move was not idiosyncratic. Humana (HUM), CVS, Elevance Health (ELV), Centene (CNC) and Clover Health (CLOV) all traded lower as analysts flagged the audit framework as a sector-wide negative. UnitedHealth, as the purest large-cap expression of Medicare Advantage economics, absorbed the heaviest selling.
Volume was substantial but did not match Tuesday's 8.05 million shares, which came on the first full session of reaction to the rule. Average daily turnover over the past three months is roughly 5 million shares. The decline pushed shares below their 60-day moving average near $397 and through the $380–$390 support zone that had held since August, leaving the stock at its lowest level in at least three months. The broader S&P 500 fell only about 0.3%, so the divergence is almost entirely company- and sector-specific rather than macro-driven. Notably, the stock had rallied about 20% year to date before this week, which gives recent buyers a large cushion of gains to protect — a dynamic that tends to accelerate selling in a $322 billion market-cap name.
The score runs from 0, meaning no meaningful news and a move normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 74 out of 100.
The verified news is genuinely material: a regulatory change that could recover billions annually from the company's largest business line, with no disclosed estimate of the company's share. It is not transformative, because the rule is proposed rather than final and the comment period runs into January 2027. The price move, meanwhile, was about 6.3 times the stock's average absolute daily change of 1.24% over the past 60 sessions, and no session in that window produced a larger one-day decline. Major news and a rare, outsized move combine into a high score, though not an extreme one.
The pivotal near-term event is the 2027 outlook, which management has promised before year-end. Consensus previously pointed to roughly $23.33 in adjusted earnings per share for 2027, and those estimates predate this week's proposal. Any explicit reserve or quantification of audit exposure would be treated as a clearing event; continued silence would likely keep a discount on the shares.
Fourth-quarter results follow in January, alongside the close of the CMS comment period. Investors will also track the Fifth Circuit's handling of related risk-adjustment litigation, medical cost trend into 2027, and any follow-through on congressional interest in insurer structure. Risks are two-sided: the final rule could soften materially, but it could also harden.
Tickeron's Trending AI Robots page curates the platform's strongest performing automated strategies under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, and only the top performers make this list. Bots vary widely by strategy, timeframe, performance metrics and traded symbols, so the page helps investors compare approaches side by side. Reviewing the current leaders is a practical way to see how systematic strategies are positioned amid volatility like this week's.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 41 cases where UNH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 68%.
The 10-day moving average for UNH crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 99 of 242 cases where UNH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 41%.
The 10-day RSI Indicator for UNH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 20 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 62 cases where UNH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 60%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNH as a result. In 55 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 28 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.
UNH moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 28 (best 1 - 100 worst), indicating outstanding price growth. UNH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of hospital and medical service plans
Industry ManagedHealthCare